3 completed, 3 recruiting, 1 suspended, 1 terminated. 4 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Suspended 1, Terminated 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Suspended 1, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Relapsed Refractory Multiple Myeloma: new trials by email Literature Review of Relapsed Refractory Multiple Myeloma trials Research Report on Relapsed Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 508 | 2026-02-23 | 2026-09-29 |
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors chimeric antigen receptor gene modified T cells - Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin | Not applicable | Recruiting | Shanxi Bethune Hospital | 45 | 2023-12-01 | 2025-01-20 |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma NEXI-002 T Cells - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | NexImmune Inc. | 9 | 2020-08-17 | 2024-01-16 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone - Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Multiple Myeloma Research Consortium | 14 | 2020-07-10 | 2025-02-14 |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone - Relapsed Refractory Multiple Myeloma | Phase 4 | Completed | Amgen | 101 | 2019-09-16 | 2026-05-11 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant Antithymocyte Globulin, Clofarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Beth Israel Deaconess Medical Center | 29 | 2008-06-01 | 2023-11-28 |
Multiple Myeloma (8) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Vascular Diseases (8) · Disease Attributes (3)
Dexamethasone (4) · pomalidomide (3) · carfilzomib (2) · daratumumab (2) · Antilymphocyte Serum (1) · Bortezomib (1) · Clofarabine (1) · Lenalidomide (1) · MLN2238 (1) · abemaciclib (1) · belantamab mafodotin (1) · cobimetinib (1) · elotuzumab (1) · enasidenib (1) · erdafitinib (1)
Multiple Myeloma Research Consortium (2) · Amgen (1) · AstraZeneca (1) · Beth Israel Deaconess Medical Center (1) · Massachusetts General Hospital (1) · NexImmune Inc. (1) · Shanxi Bethune Hospital (1)
United States (6) · China (2) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · India (1) · Italy (1) · Japan (1) · Norway (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1)
David E Avigan, MD (1) · Hearn J Cho, M.D., Ph.D. (1) · Hearn J. Cho, M.D., Ph.D. (1) · Kristi Jones (1) · Madhav V. Dhodapkar, M.D. (1) · Noopur Raje, MD (1)